Zobrazeno 1 - 10
of 141
pro vyhledávání: '"35"'
Autor:
Lassana Cissé, K. Dembele, Salimata Diarra, C.O. Guinto, Kenneth H. Fischbeck, Guida Landouré, Abdoulaye Bocoum, Mohamede E Dembélé, Oumar Samassekou
Publikováno v:
Am J Med Genet A
Variants in FA2H have been associated with a wide range of phenotypes including hereditary spastic paraplegia type 35 (SPG35); however, genetically confirmed cases have not been reported in Africa. We report here the first African family with a varia
Autor:
Richard L. Theriault, Aman U. Buzdar, Banu Arun, Daniel J. Booser, Vicente Valero, Yesmin Eralp, Kristine Broglio, Shu-Wan Kau, Gabriel N. Hortobagyi, Julie Erlichman, Ana M. Gonzalez-Angulo
Publikováno v:
Cancer. 103:2466-2472
The purpose of the current study was to describe a population of young patients with breast carcinoma, their characteristics at the time of diagnosis, and the association of these characteristics with disease recurrence and survival.Four hundred fift
Publikováno v:
Diabetic Medicine. 23:1180-1185
Aims To determine differences in pancreatic B-cell function in relation to islet antibodies at diagnosis of diabetes and 3 years later in subjects aged 35–64 years old compared with those aged 0–34 years. Methods From a population-based diabetes
Autor:
Daniel G. Miller
Publikováno v:
Medical and Pediatric Oncology. 12:224-227
After the 1945 atomic bomb explosions, attention was initially drawn to the leukemogenic effect of atomic radiation. Mortality studies over the years have shown that the leukemogenic effect has been gradually declining, and the incidence of solid tum
Autor:
Luis Edgar González-Sánchez, Leticia A. Barajas-Nava, Alejandra Contreras-Ramos, Clara Ortega-Camarillo
Publikováno v:
Journal of Diabetes. 13:792-816
This systematic review summarizes results of studies that evaluated the expression of microRNAs (miRs) in prediabetes or type 2 diabetes (T2D).The information was obtained from PubMed, EMBL-EBI, Wanfang, Trip Database, Lilacs, CINAHL, Human microRNA
Autor:
Myung-Hee Shin, Sung Noh Hong, Mi Yang, Sung-Wook Park, June Young Lee, Young-Ho Kim, Eun Ran Kim, Tae Jun Kim, Seonwoo Kim, Dong Kyung Chang
Publikováno v:
Alimentary Pharmacology & Therapeutics. 49:165-172
Background Although a higher risk of other immune-mediated diseases has been reported in inflammatory bowel disease (IBD) patients, the risk factors of immune-mediated diseases development and the effect of concomitant immune-mediated diseases on out
Autor:
Gerardo Cazarez-Navarro, Erika Martinez-Lopez, José Francisco Muñoz-Valle, Luis Humberto Govea‐Camacho, Sergio Yair Rodriguez‐Preciado, Vania Araujo‐Caballero, Enrique Ortiz‐Hernandez, Jaime Palomares‐Marin, Iván Hernández-Cañaveral
Publikováno v:
Journal of Clinical Laboratory Analysis
Background Recurrent respiratory papillomatosis (RRP) is a respiratory tract disease that affects children and adults and is characterized by the recurrent proliferation of multiple papillomas. The etiologic agent is the human papillomavirus, mainly
Autor:
Gerjan Navis, Christian Delles, Goce Spasovski, Matias Trillini, R. Göke, Lidmila Francová, Marie Frimodt-Møller, Giel Nijpels, I. Dimos, P. Girman, Alberto Ortiz, H. von der Leyen, T. Havrdova, Joline W. Beulens, Marina Noutsou, Peter Rossing, K. Adamova, Andreas L. Birkenfeld, Frederik Persson, Harald Mischak, Ivan Rychlik, Aneliya Parvanova, Marijn M. Speeckaert, Morten Lindhardt, Piero Ruggenenti, Joachim Beige, Nete Tofte, Femke Rutters, Gemma Currie, Adriaan Kooy
Publikováno v:
Diabetic Med. 35, 1375-1382 (2018)
Tofte, N, Lindhardt, M, Adamova, K, Beige, J, Beulens, J W J, Birkenfeld, A L, Currie, G, Delles, C, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Havrdova, T, Kooy, A, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Ruggenenti, P L, Rutters, F, Rychlík, I, Spasovski, G, Speeckaert, M, Trillini, M, von der Leyen, H & Rossing, P 2018, ' Characteristics of high-and low-risk individuals in the PRIORITY study : urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes ', Diabetic Medicine, vol. 35, no. 10, pp. 1375-1382 . https://doi.org/10.1111/dme.13669
Diabetic Medicine, 35(10), 1375-1382. Wiley
Diabetic Medicine, 35(10), 1375-1382. Wiley-Blackwell
Tofte, N, Lindhardt, M, Adamova, K, Beige, J, Beulens, J W J, Birkenfeld, A L, Currie, G, Delles, C, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Havrdova, T, Kooy, A, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Ruggenenti, P L, Rutters, F, Rychlík, I, Spasovski, G, Speeckaert, M, Trillini, M, von der Leyen, H & Rossing, P 2018, ' Characteristics of high-and low-risk individuals in the PRIORITY study : urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes ', Diabetic Medicine, vol. 35, no. 10, pp. 1375-1382 . https://doi.org/10.1111/dme.13669
Diabetic Medicine, 35(10), 1375-1382. Wiley
Diabetic Medicine, 35(10), 1375-1382. Wiley-Blackwell
Aim: \ud To compare clinical baseline data in individuals with Type 2 diabetes and normoalbuminuria, who are at high or low risk of diabetic kidney disease based on the urinary proteomics classifier CKD273.\ud \ud Methods: \ud We conducted a prospect
Autor:
Romain Guilhaumou, Amélie Marsot, Olivier Blin, Fabrice Michel, Olivier Paut, Estelle Chasseloup
Publikováno v:
Fundamental & Clinical Pharmacology
Fundamental & Clinical Pharmacology, Wiley, 2017, 31 (5), pp.558-566. ⟨10.1111/fcp.12291⟩
Fundamental & Clinical Pharmacology, Wiley, 2017, 31 (5), pp.558-566. ⟨10.1111/fcp.12291⟩
An external evaluation of phenobarbital population pharmacokinetic model described by Marsot et al. was performed in pediatric intensive care unit. Model evaluation is an important issue for dose adjustment. This external evaluation should allow conf
Autor:
Andrew M. Will, Bryce A. Kerlin, Michael Williams, M. Sandberg Lundblad, Diane J. Nugent, C. W. Tornøe, Manuel Carcao, B. Brand-Staufer
Publikováno v:
Haemophilia. 21:380-385
Three trials investigated the pharmacokinetics (PK) of recombinant factor XIII (rFXIII) A-subunit. To compare the PK characteristics of rFXIII among trials and different age groups of patients. Dosing with rFXIII 35 IU kg(-1) every 4th week. Blood sa